Histone deacetylase (HDAC) inhibitors, such as Belinostat, Panobinostat, or Tucidinostat have been tested in lymphomas [59], multiple myeloma [60], breast cancer [61], and thyroid cancer [62]. This evidence concerns the gene HDAC9 and thyroid cancer.